The treatment of breast cancer requires a multidisciplinary approach incorporating surgery, radiotherapy, hormonal agents, targeted therapies, and chemotherapy. Treatment decisions are influenced by disease stage, resectability, and HER2 and HR status. Targeted treatment options for the HR-positive, HER2-negative segment have expanded in the United States following the market entries of Pfizer’s Ibrance (2015) and Novartis’s Kisqali (2017). This study shines a spotlight on the current treatment dynamics for HR-positive, HER2-negative breast cancer and examines how the triple-negative breast cancer population is now managed.
Key drugs covered: